Hemoglobin and granulocyte count in infants at birth, one month and three months of age.

<p>A. At birth, group 1-infants with prenatal AZT exposure presented with significantly lower median hemoglobin (13.2 g/dl vs. 15.2 g/dl, p<0.001) than group 2-infants. At one month and at three months of age, differences in median hemoglobin between both groups were no longer significant. B. The median granulocyte count at birth was significantly lower in infants with AZT exposure during pregnancy (5.1/nl in group 1 vs. 7.3/nl in group 2, p<0.05). At one month of age, the median granulocyte count was significantly lower in group 2-infants compared to group 1-infants (3.2/nl in group 1 vs. 1.7/nl in group 2, p = 0.001). No statistically significant differences in granulocyte count were observed at three months of age.</p

Flow chart of study cohort.

<p>Study population and applied statistical tests during antenatal care visits, delivery and follow-up visits at one month and three months post-delivery.</p

Baseline characteristics of infants of group 1 and 2.

a<p>Mann-Whitney-U-test.</p>b<p>Fisher’s exact test; all other compared by t-test.</p

Baseline characteristics of mothers of group 1 and 2.

a<p>Excluded from below socio-demographic comparison.</p>b<p>Mann-Whitney-U-test; all other compared by t-test.</p

Hematological parameters of infants by group at birth, 4–6 weeks of age and 12 weeks of age.

a<p>Mann-Whitney-U-test, all other compared by t-test.</p

Summary of used adherence outcome measures.

<p>*among hospital deliveries.</p

Influence of sociodemographic, economic and health-related factors on pre-delivery AZT adherence level.

<p>*Mann-Whitney U-Test.</p

Profile of cohort and analyses.

<p>This figure is illustrating the formation of the cohort and of its different subgroups, including women observed in the antenatal period, women accepting/declining antenatal prophylaxis, women lost to follow-up (LTFU), women observed intra/postpartumly and infants observed postpartumly. It is indicated which analyses have been performed within the respective subgroups and where the results of those analyses are shown.</p

Oligonucleotide sequences of primers used in outer and allele-specific PCR (ASPCR).

<p>Oligonucleotide sequences of primers used in outer and allele-specific PCR (ASPCR).</p

Distribution of drug-resistant HIV-1 variants after complex antiretroviral prophylaxis in 50 Tanzanian women.

<p>Distribution of drug-resistant HIV-1 variants after complex antiretroviral prophylaxis in 50 Tanzanian women.</p